

Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): final results from a Phase 2 study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC)

<u>D.M. O'Malley</u>¹, M. Neffa², B.J. Monk³, T. Melkadze⁴, A. Kryzhanivska⁵, I. Bulat⁶, T.M. Meniawy⁷, I. Bondarenko⁸, W. Ortuzar Feliu⁹, M. Ancukiewicz⁹, I. Lugowska¹⁰

¹Division of Gynecologic Oncology, The Ohio State University/James Comprehensive Cancer Center, Columbus, Ohio; ²Department of Surgery, CI of Healthcare Regional Clinical Specialized Dispensary of the Radiation Protection, Kharvik, Ukraine; ³Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, Arizona; ⁴Medical Oncology, Research Institute of Clinical Medicine, Tbilisi, Georgia; ⁵Regional Clinical Oncology Center, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine; ⁶ARENSIA Exploratory Medicine, Institute of Oncology Unit, Chisinau, Moldova; ⁷Linear Clinical Research, Nedlands, Australia; ⁸Department of Chemotherapy, Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine, Dnipropetrovsk, Ukraine; ⁹Clinical Development, Agenus Inc., Lexington, Massachusetts; ¹⁰Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland.



DECLARATION OF INTERESTS

David M. O'Malley

Personal financial interests: Advisory boards and/or Consult: Agenus, Ambry, Amgen, Abbvie, Cordgenics, Genentech/Roche, AstraZeneca, Clovis Oncology, Eisai, Merck, Tesaro, GlaxoSmithKline, Iovance, Immunogen, GOG-Foundation, Janssen/J&J, LEAP Therapeutics, Mersana, Myriad, Novocure, Regeneron, TapImmune/Marker Therapeutics, Tarveda, Seattle Genetics.

Commercial Medical Education Providers: Prime Oncology, Target Oncology, RTP, PER, BioAscend, OncLive, TRM Oncology.

Institutional support for clinical research (local PI): Agenus, Abbvie, Genentech/Roche, AstraZeneca, Clovis Oncology, Eisai, Merck, Tesaro, GlaxoSmithKline, Immunogen, GOG-Foundation, Janssen/J&J, LEAP Therapeutics, Mersana, Novocure, Regeneron, GenMab, Seattle Genetics Advaxis Inc. VentiRx, Array Biopharma, EMD Serono, Ergomed, Ajinomoto Inc., Ludwig Cancer Research, Stemcentrx, Inc, Cerulean Pharma, GOG Foundation, Bristol-Myers Squibb Co, Serono Inc, Tracon Pharmaceuticals, Yale University, New Mexico Cancer Care Alliance, INC Research, Inc, inVentiv Health Clinical, Iovance Biotherapeutics, PRA Intl, NCI/NIH.

Organizational and leadership roles: GOG-P ovarian cancer clinical trial lead; SGO Finance Committee; NRG Developmental Therapeutics and Ovarian Cancer working groups; GCSC Ovarian Task Force **Membership:** ESMO, ASCO, SGO, NRG/GOG



C-550 Study Design

NCT03495882 – Global phase 2 trial (Europe, United States, Australia, South America)


Population	Treatment (for up to 24 months)	Follow-up
 Histologically confirmed SCC, ASC, adenocarcinoma of the cervix relapsed after platinum-based treatment Measurable disease ECOG performance status 0–1 	Balstilimab 3 mg/kg Q2W + Zalifrelimab 1 mg/kg Q6W (N=155)	Imaging every 6 weeks through 2 years

- **Primary endpoint:** ORR by RECIST v1.1 (per Independent Review Committee)
- Secondary endpoints: DOR, PFS, OS

ASC, adenosquamous carcinoma; DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; SCC, squamous cell carcinoma.



Study Enrollment





David M. O'Malley

Characteristic	N = 155
Age, median (range)	50 (24-76)
Tumor Histology	
Squamous cell carcinoma	109 (70.3)
Adenocarcinoma	42 (27.1)
Adenosquamous	4 (2.6)
ECOG PS	
0	89 (57.4)
1	66 (42.6)
PD-L1 tumor expression status	
Positive (CPS ≥1%)	88 (56.8)
Negative (CPS <1%)	39 (25.2)
Unknown	28 (18.1)
Prior therapy exposure	
Platinum	154 (99.4)
Taxane	122 (78.7)
Bevacizumab	51 (32.9)



Characteristic	N = 155
Age, median (range)	50 (24-76)
Tumor Histology	
Squamous cell carcinoma	109 (70.3)
Adenocarcinoma	42 (27.1)
Adenosquamous	4 (2.6)
ECOG PS	
0	89 (57.4)
1	66 (42.6)
PD-L1 tumor expression status	
Positive (CPS ≥1%)	88 (56.8)
Negative (CPS <1%)	39 (25.2)
Unknown	28 (18.1)
Prior therapy exposure	
Platinum	154 (99.4)
Taxane	122 (78.7)
Bevacizumab	51 (32.9)



Characteristic	N = 155
Age, median (range)	50 (24-76)
Tumor Histology	
Squamous cell carcinoma	109 (70.3)
Adenocarcinoma	42 (27.1)
Adenosquamous	4 (2.6)
ECOG PS	
0	89 (57.4)
1	66 (42.6)
PD-L1 tumor expression status	
Positive (CPS ≥1%)	88 (56.8)
Negative (CPS <1%)	39 (25.2)
Unknown*	28 (18.1)
Prior therapy exposure	
Platinum	154 (99.4)
Taxane	122 (78.7)
Bevacizumab	51 (32.9)




*PD-L1 status not determined due to missing/insufficient biopsy tissue for analysis or samples were non-evaluable

Characteristic	N = 155
Age, median (range)	50 (24-76)
Tumor Histology	
Squamous cell carcinoma	109 (70.3)
Adenocarcinoma	42 (27.1)
Adenosquamous	4 (2.6)
ECOG PS	
0	89 (57.4)
1	66 (42.6)
PD-L1 tumor expression status	
Positive (CPS ≥1%)	88 (56.8)
Negative (CPS <1%)	39 (25.2)
Unknown	28 (18.1)
Prior therapy exposure	
Platinum	154 (99.4)
Taxane	122 (78.7)
Bevacizumab	51 (32.9)




Clinical Activity



ORR, N (%)

32 (25.6)


Clinical Activity



ORR, N (%)

32 (25.6)

Clinical Activity




ORR, N (%)

32 (25.6)

Kaplan-Meier Survival Estimates

Median duration of follow-up: 21 months



PD-L1⁺ subset mOS: 15.7 mo (95% CI, 7.6, 21.1)



Safety Summary

Treatment-related AEs	N (%)
Any	110 (71.0)
Hypothyroidism	26 (16.8)
Diarrhea	22 (14.2)
Fatigue	18 (11.6)
Grade ≥ 3	31 (20.0)
ALT increased	4 (2.6)
Diarrhea	3 (1.9)
Leading to dose interruption	19 (12.3)
Leading to dose discontinuation	12 (7.7)

Immune-mediated AEs	N (%)
Any	69 (44.5)
Hypothyroidism	22 (14.2)
Hyperthyroidism	11 (7.1)
Diarrhea	11 (7.1)
Pruritis	7 (4.5)



Summary

- Largest study to date evaluating dual PD-1/CTLA-4 checkpoint blockade in patients with R/M CC
- The balstilimab + zalifrelimab combination elicited high and durable response rates, compelling overall survival, and good tolerability
- The combination was particularly effective in driving responses in PD-L1-positive patients, and was more broadly active in subsets of R/M CC patients with poorer risk features
- This novel regimen provides meaningful clinical benefit for a patient population with significant unmet need and lack of effective therapies

